Trials / Completed
CompletedNCT02486354
Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy
Safety and Efficacy of Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy: a Single-arm, Phase 3 Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 128 (actual)
- Sponsor
- Betta Pharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study was a single-arm, multi-center, prospective, phase 3 trial aimed to evaluate the efficacy and safety of icotinib in patients with locally advanced or metastatic NSCLC after failure of at least one platinum-based chemotherapy regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | icotinib | Patients were administered with oral icotinib (tablet form, 125 mg) three times daily within two days after enrollment until disease progression or unacceptable toxicity. |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2011-10-01
- Completion
- 2012-04-01
- First posted
- 2015-07-01
- Last updated
- 2015-07-01
Locations
10 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02486354. Inclusion in this directory is not an endorsement.